Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder

Dong Hwan Yun, Chi Un Pae, Antonio Drago, Laura Mandelli, Diana De Ronchi, Ashwin A. Patkar, In Ho Paik, Alessandro Serretti, Jung Jin Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment. Methods A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (± 19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T. rs2005976 G/A, rs760761 C/T and rs2619522 A/C). Results There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors. Conclusion Although the small number of subjects is an important limitation in our study. DTNBP1 does not seem to be involved in acute antimanic efficacy.

Original languageEnglish
Pages (from-to)102-105
Number of pages4
JournalPsychiatry Investigation
Volume5
Issue number2
Publication statusPublished - Jun 2008

Fingerprint

Antimanic Agents
Bipolar Disorder
Genes
Carbamazepine
Valproic Acid
Lithium
Therapeutics

Keywords

  • Antimanic agents
  • Bipolar disorder
  • Dysbindin
  • Pharmacogenetics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Yun, D. H., Pae, C. U., Drago, A., Mandelli, L., De Ronchi, D., Patkar, A. A., ... Kim, J. J. (2008). Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder. Psychiatry Investigation, 5(2), 102-105.

Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder. / Yun, Dong Hwan; Pae, Chi Un; Drago, Antonio; Mandelli, Laura; De Ronchi, Diana; Patkar, Ashwin A.; Paik, In Ho; Serretti, Alessandro; Kim, Jung Jin.

In: Psychiatry Investigation, Vol. 5, No. 2, 06.2008, p. 102-105.

Research output: Contribution to journalArticle

Yun, DH, Pae, CU, Drago, A, Mandelli, L, De Ronchi, D, Patkar, AA, Paik, IH, Serretti, A & Kim, JJ 2008, 'Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder', Psychiatry Investigation, vol. 5, no. 2, pp. 102-105.
Yun DH, Pae CU, Drago A, Mandelli L, De Ronchi D, Patkar AA et al. Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder. Psychiatry Investigation. 2008 Jun;5(2):102-105.
Yun, Dong Hwan ; Pae, Chi Un ; Drago, Antonio ; Mandelli, Laura ; De Ronchi, Diana ; Patkar, Ashwin A. ; Paik, In Ho ; Serretti, Alessandro ; Kim, Jung Jin. / Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder. In: Psychiatry Investigation. 2008 ; Vol. 5, No. 2. pp. 102-105.
@article{ec7f68da1b1c45c38cbc0dee61451e9c,
title = "Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder",
abstract = "Objective We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment. Methods A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (± 19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T. rs2005976 G/A, rs760761 C/T and rs2619522 A/C). Results There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors. Conclusion Although the small number of subjects is an important limitation in our study. DTNBP1 does not seem to be involved in acute antimanic efficacy.",
keywords = "Antimanic agents, Bipolar disorder, Dysbindin, Pharmacogenetics",
author = "Yun, {Dong Hwan} and Pae, {Chi Un} and Antonio Drago and Laura Mandelli and {De Ronchi}, Diana and Patkar, {Ashwin A.} and Paik, {In Ho} and Alessandro Serretti and Kim, {Jung Jin}",
year = "2008",
month = "6",
language = "English",
volume = "5",
pages = "102--105",
journal = "Psychiatry Investigation",
issn = "1738-3684",
publisher = "Korean Neuropsychiatric Association",
number = "2",

}

TY - JOUR

T1 - Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder

AU - Yun, Dong Hwan

AU - Pae, Chi Un

AU - Drago, Antonio

AU - Mandelli, Laura

AU - De Ronchi, Diana

AU - Patkar, Ashwin A.

AU - Paik, In Ho

AU - Serretti, Alessandro

AU - Kim, Jung Jin

PY - 2008/6

Y1 - 2008/6

N2 - Objective We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment. Methods A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (± 19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T. rs2005976 G/A, rs760761 C/T and rs2619522 A/C). Results There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors. Conclusion Although the small number of subjects is an important limitation in our study. DTNBP1 does not seem to be involved in acute antimanic efficacy.

AB - Objective We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment. Methods A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (± 19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T. rs2005976 G/A, rs760761 C/T and rs2619522 A/C). Results There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors. Conclusion Although the small number of subjects is an important limitation in our study. DTNBP1 does not seem to be involved in acute antimanic efficacy.

KW - Antimanic agents

KW - Bipolar disorder

KW - Dysbindin

KW - Pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=46949101020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46949101020&partnerID=8YFLogxK

M3 - Article

C2 - 20046352

AN - SCOPUS:46949101020

VL - 5

SP - 102

EP - 105

JO - Psychiatry Investigation

JF - Psychiatry Investigation

SN - 1738-3684

IS - 2

ER -